Transcranial Photobiomodulation for Spasticity in Pediatric Cerebral Palsy: A Scoping Review of Neurodevelopmental Considerations, Treatment Protocols, Functional Outcomes, and Methodological Gaps
Brain Sciences · 28.02.2026 · 16 (3) · 272
DOI: 10.3390/brainsci16030272 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 28.02.2026. Verfasst von Amalio Jiménez und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Carrick Institute, Cape Canaveral, FL 32920, USA. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Spasticity, affecting over 80% of children with cerebral palsy (CP), is a major source of disability. Transcranial photobiomodulation (tPBM) is a promising non-invasive neuromodulatory intervention, but evidence for its use in pediatric CP spasticity is fragmented and limited.
Objective
This scoping review aimed to systematically map the literature to characterize neurodevelopmental considerations, treatment protocols, functional outcomes, and methodological gaps related to tPBM for spasticity in pediatric CP.
Methods
The review followed the PRISMA extension for Scoping Reviews (PRISMA-ScR). A systematic search was performed across eight databases from January 2000 to September 2025. The PCC framework guided inclusion of studies involving children/adolescents (0–18 years) with CP and spasticity, investigating PBM with a primary focus on transcranial application.
Results
From 345 records, only five primary studies (total n = 45 children) met the inclusion criteria. The evidence base is severely limited and heterogeneous, with only two of the five studies applying tPBM. A profound lack of protocol standardization was identified, with frequent reports that are internally inconsistent or contain physically implausible dosimetry reporting. Methodological quality was pre-preliminary, with no sham-controlled or adequately blinded trials. Although all studies reported reductions in spasticity and/or motor improvements, the high risk of bias prevents attribution of the effects to tPBM.
Conclusions
The evidence supporting tPBM for spasticity in pediatric CP is in a pre-preliminary stage, defined by a critically small number of studies, a pervasive lack of methodological rigor, and an absence of pediatric-specific safety protocols. The field requires an immediate pivot to foundational, sham-controlled, double-blind trials with standardized dosimetry before tPBM can be considered anything other than an unproven experimental intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Carrick Institute, Cape Canaveral, FL 32920, USA.
- Centre for Mental Health Research in Association, The University of Cambridge, Cambridge CB2 1TN, UK.
- College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
- Burnett School of Biomedical Science, University of Central Florida, Orlando, FL 32827, USA.
- Department of Health Professions Education, MGH Institute for Health Professions, Boston, MA 02129, USA.
- Faculty of Physical Education, Ningbo University, Ningbo 315000, China.
ORCID-Profile: Amalio Jiménez, Frederick R Carrick, Monèm Jemni
Zitieren
APA
Jiménez, A., Carrick, F. R., & Jemni, M. (2026). Transcranial Photobiomodulation for Spasticity in Pediatric Cerebral Palsy: A Scoping Review of Neurodevelopmental Considerations, Treatment Protocols, Functional Outcomes, and Methodological Gaps. Brain Sciences, 16(3), 272. https://doi.org/10.3390/brainsci16030272
Vancouver
Jiménez A, Carrick FR, Jemni M. Transcranial Photobiomodulation for Spasticity in Pediatric Cerebral Palsy: A Scoping Review of Neurodevelopmental Considerations, Treatment Protocols, Functional Outcomes, and Methodological Gaps. Brain Sciences. 2026;16(3):272. doi:10.3390/brainsci16030272
BibTeX
@article{Jimnez2026,
author = {Jiménez, Amalio and Carrick, Frederick R and Jemni, Monèm},
title = {Transcranial Photobiomodulation for Spasticity in Pediatric Cerebral Palsy: A Scoping Review of Neurodevelopmental Considerations, Treatment Protocols, Functional Outcomes, and Methodological Gaps},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {3},
pages = {272},
doi = {10.3390/brainsci16030272}
}
EUVIMED